Mode
Text Size
Log in / Sign up
Phase 2 N=24 Treatment

Effects of PRK 124 Lotion in Acne Rosacea

Acne Rosacea

Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Dec 2013
Primary outcome: Primary: Erythema Severity — 44.53 Erythema percent improvement

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
PRK 124 (Other)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
University of California, Irvine
Primary completion
Feb 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Erythema Severity
44.53
PRIMARY
Inflammatory Lesion Count
89
PRIMARY
Telangiectasia Severity
27.88
SECONDARY
Skin Tolerance
SECONDARY
Skin Photodamage
SECONDARY
Transepidermal Water Loss (TEWL)
SECONDARY
Cosmetic Acceptability

Summary

The purpose of this open-label study is to determine the tolerance and efficacy of twice-daily application of PRK 124 (Pyratine-6)(0.125%) moisturizing lotion for improving the signs and symptoms of mild to moderate facial rosacea.

Eligibility Criteria

Inclusion Criteria

  • be at least 21 years old
  • be in reasonably good health as defined by the study doctor
  • have routine laboratory tests to evaluate your blood cell count, and kidney and liver function
  • for females of child-bearing age, not be pregnant or nursing and have a negative urine pregnancy test (except if surgically sterile or at least 1 year menopausal)
  • for females, agree to use medically acceptable forms of birth control throughout the entire study (medically acceptable forms of birth control include oral contraceptive ["the pill"], implants such as Norplant®, injectable progesterone [Depo-provera®], diaphragm and spermicide or condoms and spermicide)
  • must have mild to moderate acne rosacea
  • be willing to refrain from using non-approved lotions, moisturizer, cleansers or lotions on affected facial areas during the treatment period
  • be capable of understanding and giving written, voluntary informed consent before study screening
  • be willing to consent to facial photographs at baseline and each follow-up visit to monitor treatment with the test product.

Exclusion Criteria

  • have a history or evidence of any chronic or reoccurring skin disease or disorder (e.g., psoriasis, eczema, etc.) affecting the face
  • have known or suspected hypersensitivity to study treatment or any of its ingredients
  • have used systemic retinoids within 6 months prior to study entry (e.g., acitretin, isotretinoin)
  • have received treatment with systemic corticosteroids (e.g. prednisone) or antibiotics within 1 month
  • have used topical treatment to the face with retinoids (e.g. tretinoin, adapalene), or antibiotics or corticosteroids, within 2 weeks prior to study entry
  • are unwilling to use a sunscreen with an SPF of 30 during the study
  • have participated in any clinical trial involving an investigational drug or cosmetic product or procedure within the past 30 days
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00580723). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search